Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

New study reveals potential cognitive benefits of Shingrix vaccine. The shingles shot may offer protection against dementia, especially in women.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

(Reuters) - Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Based on the shingles incidence rate from the placebo arm North American cohort of ZOSTER-006, a Phase 3 trial of Shingrix, 10 of the 876 participants in the Phase 2 trial should have been diagnosed ...

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...